Kenvue Inc. (NYSE:KVUE) Receives $23.00 Consensus Price Target from Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have been assigned an average rating of “Hold” from the fourteen research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $23.00.

A number of equities analysts have recently commented on KVUE shares. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Canaccord Genuity Group dropped their price objective on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Bank of America lifted their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Leo Wealth LLC increased its holdings in Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares during the period. Alerus Financial NA increased its holdings in Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after purchasing an additional 491 shares during the period. Kiley Juergens Wealth Management LLC increased its holdings in Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock valued at $579,000 after purchasing an additional 500 shares during the period. Principle Wealth Partners LLC increased its holdings in Kenvue by 3.7% during the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock valued at $303,000 after purchasing an additional 500 shares during the period. Finally, Wolff Wiese Magana LLC increased its holdings in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after purchasing an additional 501 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $21.94 on Thursday. The stock has a fifty day simple moving average of $21.32 and a two-hundred day simple moving average of $22.07. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46. The firm has a market cap of $42.07 billion, a price-to-earnings ratio of 41.40, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts anticipate that Kenvue will post 1.05 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.74%. Kenvue’s dividend payout ratio is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.